BACKGROUND/AIM: Radiotherapy is widely accepted as the treatment of choice for early glottic squamous cell carcinoma (EGSCC), although it varies greatly with respect to dose, dose per fraction, and treatment techniques. The study aim was to evaluate the use of accelerated fractionation strategy (AFS) for EGSCC in standard clinical practice. PATIENTS AND METHODS: Patients treated with definitive radiotherapy for EGSCC between 2008 and 2019 were retrospectively identified and received either conventional fractionation, hypofractionation, or hyperfractionation. RESULTS: One hundred six patients were analyzed, and 19, 71, and 16 patients underwent conventional fractionation, hypofractionation, and hyperfractionation, respectively. The median follow-up was 56 months. The 5-year local control and overall survival rates were 79% and 83%; 78% and 79%; and 87% and 77%, respectively, and no significant difference was observed between the fractionation schedules. CONCLUSION: Our findings confirmed the utility of AFS in standard clinical practice and support its use for patients with EGSCC. Copyright
BACKGROUND/AIM: Radiotherapy is widely accepted as the treatment of choice for early glottic squamous cell carcinoma (EGSCC), although it varies greatly with respect to dose, dose per fraction, and treatment techniques. The study aim was to evaluate the use of accelerated fractionation strategy (AFS) for EGSCC in standard clinical practice. PATIENTS AND METHODS: Patients treated with definitive radiotherapy for EGSCC between 2008 and 2019 were retrospectively identified and received either conventional fractionation, hypofractionation, or hyperfractionation. RESULTS: One hundred six patients were analyzed, and 19, 71, and 16 patients underwent conventional fractionation, hypofractionation, and hyperfractionation, respectively. The median follow-up was 56 months. The 5-year local control and overall survival rates were 79% and 83%; 78% and 79%; and 87% and 77%, respectively, and no significant difference was observed between the fractionation schedules. CONCLUSION: Our findings confirmed the utility of AFS in standard clinical practice and support its use for patients with EGSCC. Copyright
Authors: Lucas Gomes Sapienza; Matthew Stephen Ning; Senzo Taguchi; Vinícius Fernando Calsavara; Antônio Cássio de Assis Pellizzon; Maria José Leite Gomes; Luiz Paulo Kowalski; Glauco Baiocchi Journal: Oral Oncol Date: 2019-04-08 Impact factor: 5.337
Authors: Trevor J Bledsoe; Henry S Park; John M Stahl; Wendell G Yarbrough; Barbara A Burtness; Roy H Decker; Zain A Husain Journal: J Natl Cancer Inst Date: 2017-10-01 Impact factor: 13.506
Authors: Abdallah S R Mohamed; Blaine D Smith; Joshua B Smith; Parag Sevak; Jessica S Malek; Aasheesh Kanwar; Theodora Browne; G Brandon Gunn; Adam S Garden; Steven J Frank; William H Morrison; Jack Phan; Mark Zafereo; Heath Skinner; Stephen Y Lai; Katherine A Hutcheson; Jan S Lewin; Amy E Hessel; Apurva A Thekdi; Randal S Weber; Clifton D Fuller; David I Rosenthal Journal: Laryngoscope Date: 2019-02-12 Impact factor: 3.325
Authors: William A Stokes; Priscilla K Stumpf; Bernard L Jones; Patrick J Blatchford; Sana D Karam; Ryan M Lanning; David Raben Journal: Oral Oncol Date: 2017-07-18 Impact factor: 5.337
Authors: William M Mendenhall; John W Werning; Russell W Hinerman; Robert J Amdur; Douglas B Villaret Journal: Cancer Date: 2004-05-01 Impact factor: 6.860
Authors: Andy Trotti; Qiang Zhang; Søren M Bentzen; Bahman Emami; M Elizabeth Hammond; Christopher U Jones; William H Morrison; Stephen M Sagar; John A Ridge; Karen K Fu; K Kian Ang Journal: Int J Radiat Oncol Biol Phys Date: 2014-07-08 Impact factor: 7.038
Authors: Assaf Moore; Robert B Den; Aaron Popovtzer; Hadar Goldvaser; Noa Gordon; Daniel A Goldstein Journal: Head Neck Date: 2020-01-24 Impact factor: 3.147
Authors: Mark C Korpics; W Tyler Turchan; Michael K Rooney; Matthew Koshy; Michael T Spiotto Journal: Cancers (Basel) Date: 2019-12-12 Impact factor: 6.639